Number of pay-for-delay deals remains low, says FTC

The number of potentially anticompetitive patent infringement settlements between brand drugmakers and generic competitors remained low in 2017, according to the Federal Trade Commission (FTC).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Tris blocks Actavis’ ADHD generic

10 December 2020 New Jersey-based Tris Pharma has won a ruling blocking Teva-owned Actavis from launching a generic version of attention deficit and hyperactivity disorder drug Quillivant XR.

Big Pharma

EC fines Teva €60.5m over pay-for-delay deal

27 November 2020 The European Commission has fined Teva and its subsidiary Cephalon €60.5 million for agreeing to delay a cheaper generic version of sleep disorder drug modafinil.

Big Pharma

‘Considerable increase’ in pay-for-delay settlements: FTC report

24 May 2019 The number of ‘pay-for-delay’ patent settlements reached in fiscal year 2016 represented a “considerable increase” from the previous year, according to a Federal Trade Commission report released yesterday, May 23, though there has been a considerable reduction in the most problematic settlements since 2013.

More on this story

Americas

Tris blocks Actavis’ ADHD generic

10 December 2020 New Jersey-based Tris Pharma has won a ruling blocking Teva-owned Actavis from launching a generic version of attention deficit and hyperactivity disorder drug Quillivant XR.

Big Pharma

EC fines Teva €60.5m over pay-for-delay deal

27 November 2020 The European Commission has fined Teva and its subsidiary Cephalon €60.5 million for agreeing to delay a cheaper generic version of sleep disorder drug modafinil.

Big Pharma

‘Considerable increase’ in pay-for-delay settlements: FTC report

More on this story

Americas

Tris blocks Actavis’ ADHD generic

10 December 2020 New Jersey-based Tris Pharma has won a ruling blocking Teva-owned Actavis from launching a generic version of attention deficit and hyperactivity disorder drug Quillivant XR.

Big Pharma

EC fines Teva €60.5m over pay-for-delay deal

27 November 2020 The European Commission has fined Teva and its subsidiary Cephalon €60.5 million for agreeing to delay a cheaper generic version of sleep disorder drug modafinil.

Big Pharma

‘Considerable increase’ in pay-for-delay settlements: FTC report